PMID- 26044841
OWN - NLM
STAT- MEDLINE
DCOM- 20160922
LR  - 20151204
IS  - 1827-1839 (Electronic)
IS  - 0392-9590 (Linking)
VI  - 34
IP  - 6
DP  - 2015 Dec
TI  - Sulodexide suppresses inflammation in patients with chronic venous insufficiency.
PG  - 589-96
AB  - AIM: According to previously performed studies, inflammation plays a crucial role 
      in vein wall and leg tissue injury related to chronic venous insufficiency (CVI) 
      development. Sulodexide (SUL) is a balanced mix of glycosaminoglycans with 
      potential anticoagulant and profibrinolytic activity, also protecting endothelial 
      cells and suppressing inflammatory reactions in various vascular disease-related 
      conditions. The goal of the present study was to evaluate the anti-inflammatory 
      action of SUL in patients with CVI. METHODS: The study was performed on a group 
      of 11 patients with chronic venous disease (stage C5 according to CEAP 
      classification). The mean age of the patients was 58.4+/-7.7 years, and none of 
      them were diabetic. The patients were treated for 8 weeks with 
      orally-administered SUL (2 x 500 LSU/day). Blood samples were collected at the 
      start and at the end of the study for measurement of MMP-9, IL-6 and monocyte 
      chemoattractant protein-1 (MCP-1). Additionally, the effect of the obtained serum 
      samples on the function of human venous endothelial cells (HVEC) in in-vitro 
      culture was evaluated. RESULTS: After treatment with SUL, the serum concentration 
      of MMP-9 (ng/mL) decreased from 6.50+/-3.48 to 5.41+/-1.36, P<0.05, and the 
      concentration of IL-6 (pg/mL) decreased from 11.5+/-3.4 to 10.1+/-2.3, P<0.005. There 
      was also a trend of decreased serum MCP-1 (pg/mL) from 31.3+/-23.0 before treatment 
      to 27.1+/-10.7 at the end. Intracellular generation of oxygen-derived free radicals 
      in HVEC maintained in in-vitro culture was lower in the serum samples collected 
      after treatment with SUL: 3.09+/-0.35 abs/mug protein vs. 3.63+/-0.32 abs/mug protein, 
      at the start, P<0.05. Synthesis of IL-6 was lower in HVEC exposed in vitro to 
      serum collected at the end of SUL treatment: 1.02+/-0.31 ng/mug cell protein vs. 
      1.32+/-0.41 ng/mug cell protein before SUL treatment. The proliferation rate of HVEC 
      was similar in serum collected at the beginning and at the end of SUL treatment. 
      CONCLUSION: We conclude that treatment with SUL in patients with CVI reduces 
      intravascular inflammation and is protective for the endothelial cells and for 
      the extracellular matrix changes related to metalloproteinase expression.
FAU - Urbanek, T
AU  - Urbanek T
AD  - Department of General and Vascular Surgery, Medical University of Silesia, 
      Katowice, Poland - urbanek.tom@interia.pl.
FAU - Zbigniew, K
AU  - Zbigniew K
FAU - Begier-Krasinska, B
AU  - Begier-Krasinska B
FAU - Baum, E
AU  - Baum E
FAU - Breborowicz, A
AU  - Breborowicz A
LA  - eng
PT  - Journal Article
DEP - 20150605
PL  - Italy
TA  - Int Angiol
JT  - International angiology : a journal of the International Union of Angiology
JID - 8402693
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anticoagulants)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Glycosaminoglycans)
RN  - 0 (Interleukin-6)
RN  - 75HGV0062C (glucuronyl glucosamine glycan sulfate)
RN  - EC 3.4.24.35 (MMP9 protein, human)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Anticoagulants/*administration & dosage
MH  - Chemokine CCL2/blood
MH  - Chronic Disease
MH  - Endothelial Cells/metabolism
MH  - Female
MH  - Glycosaminoglycans/*administration & dosage
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Interleukin-6/blood
MH  - Male
MH  - Matrix Metalloproteinase 9/blood
MH  - Middle Aged
MH  - Treatment Outcome
MH  - Venous Insufficiency/*drug therapy
EDAT- 2015/06/06 06:00
MHDA- 2016/09/23 06:00
CRDT- 2015/06/06 06:00
PHST- 2015/06/06 06:00 [entrez]
PHST- 2015/06/06 06:00 [pubmed]
PHST- 2016/09/23 06:00 [medline]
AID - R34Y9999N00A150046 [pii]
PST - ppublish
SO  - Int Angiol. 2015 Dec;34(6):589-96. Epub 2015 Jun 5.